Case Analysis - Amgen Inc.

Biotech companies’ values are primarily driven by intellectual property, they do not need to rely much on their suppliers. These companies also have relatively easy access to sources of raw materials (such as chemicals), scientific tools, computers and testing equipment.

Ecton is going to position the company to be acquired but the board of directors and clinical advisors has some concerns about the ramifications of that plan. This paper evaluates Cannon’s Phase III Plan on March 1998. Cannon proposed a path for the next year containing five major points (Edward, 1999, 8 and 9). The bottom line of this proposal is positioning Ecton to be acquired by the end of the 1998. One of the crucial concerns of this acquisition is the possible effects on “Ecton’s product development process”. Another concern Cannon holds is the ability of Ecton to penetrate a very harsh market fills with big, established, and advanced manufacturers. Also, Cannon is not sure on how to approach specific market

Cynthia Robbins-Roth is a strategic planner and business consultant to the biotechnology industry, named one of the Top 25 Biotech All-Stars by popular business magazine Forbes. Her book, published in year 2000, provides a broad overview of many biotech topics and draws upon her experience and skill as a keen businesswoman. The engaging and informative work initially details the establishment and growth of the biotechnology industry, as well as its historical origins and information on key players in its founding. Throughout her account of this “dynamic” industry’s early struggles, great successes, and current difficulties, Robbins-Roth presents her opinion of the industry’s current viability and hopes of the future product pipeline. Robbins-Roth predicts a revolutionary change in health management and treatment, which combined with the growing aged population, will produce sufficient demand to propel the biotechnology industry past the well-established small molecule pharmaceutical companies. She asserts that the biotechnology companies will emerge as the leaders in the world’s medical research and development. Robbins-Roth further explains the intricacies of financing a biotechnology venture, the necessity of efficient risk management, and the difficulty of selling an idea to non-scientist investors.

Nucleon is faced with a decision that has a long-term implication for its future in a highly competitive drug industry. With its first product, CRP-1 ready for human clinical trials, Nucleon must decide on its manufacturing strategy. For Phases I & II, Nucleon has three options available including building a new pilot plant in-house, contracting an outside manufacturing firm or licensing the product to another company. For Phase III, Nucleon could either license out manufacturing and marketing rights or vertically integrate into commercial manufacturing. Accordingly, Nucleon has 5 options under consideration: 1) Option 1: build a new pilot plant for Phases I & II and build a manufacturing plant for Phase III; ii) Option 2: build a new pilot

The book “from Alchemy to IPO the business of Biotechnology” is a synopsis of the biotech industry from its inception to late 1900’s . Author Cynthia Robbins – Roth writes a first hand narration from amidst the blooming industry as she was one of the first senior scientist to be recruited by Genentech. The book gives a complete picture from the roots of biotech , the major milestones achieved and the process of getting the product out to the market. It also covers the financers, venture capitalist and the common man’s view of the biotech industry from time to time, during its progression.

As Amgen expands internationally, Dun Laoghaire will enhance its global production capability, ensuring continuity of supply of Amgen medicines for seriously ill patients worldwide. A significant research and development investment will be used in order to transform the Dun Laoghaire facility (utilising a major technology process enhancement to transform the plant) into one of the leading biotechnology manufacturing sites in the world. The company’s Irish commercial office is located in Santry, Co

There are several rewards to consider with expansion of Biocon. Currently in India, there is a growing market for contract research organization and the growth of Biocon falls right within this opportunity. The growth is expected to last for more than few years with a rate that looks promising. Clinigene is expected to reap revenues much higher than the current Biocon and Syngene combined (Kalegaonkar A., Nov 4, 2008). It will take clinical studies to a higher level with better options in terms of drug manufacturing. With other countries ready to outsource the service of clinical studies, Clinigene’s future looks bright.

The Synaptic Corporation is a biotechnology company based out of San Diego, CA. The company develops drugs based on proteins and peptides. To date, one drug has been approved by the Federal Drug Administration (FDA) but there are two other drugs that are currently in clinical trials. Synaptic is a fairly large company with 1,200 employees. The two main departments that are of issue are the Information Management (IM) and the Computational Biology department. There are no clear define roles and responsibilities of the Synaptic staff and there is a lack of leadership and organizational culture. Additionally, it is unsure exactly what Synapic’s organizational goals and objectives are. This paper will provide a

Prior to each decision that has to be made, the management team has to set realistic goals. By setting realistic goals we will be able to strategically figure out which direction is most suitable for the direction that we are aiming towards. Realistically as we analyze the world and make comparisons on how businesses functioned 15 years ago to now we would see many differences. By figuring out ways to remove the middleman, that opens doors to create new opportunities. For example, enhancing technology within manufacturers in our various markets.

EXECUTIVE SUMMARYSilicon Valley Medical Technologies (SIVMED) was founded as a research and development firm. In the beginning, SIVMED performed its own basic research, obtained patents on promising technologies, and then either sold or licensed the technologies to other firms which marketed the products. The firm has since then grown and is now contracted to perform research and testing for larger genetic engineering firms, biotechnology firms, the US government, and is now widely recognized as the leader in an emerging growth industry. SIVMED's founders were relatively wealthy individuals when they started company, and they committed a great deal of their own funds to the venture. Their personal funds, however, were soon exhausted by the

Technology is the driving force of health care (Williams & Torrens, page 362). William & Torrens describes it as the health care systems delivery mechanism for developing the nation’s biological research laboratories and clinical practices (page 362). The development, testing, and distribution of technological advances are fundamental to improving the nation’s health (Williams & Torrens, page 363). For example in Chapter One we discussed the development of health care technology by an industrial group. Health technologies can be seen to range from the simplest new variation on a previously standard medication to the development of an entirely new medication or device (Williams & Torrens, page 21). Cost-benefit analysis and other analytical techniques must be utilized along with clinical evaluations to keep technology in proper perspective (Williams & Torrens, page 363). Technological changes that have occurred in recent years recognize our greatest biological achievements (Williams & Torrens, page 363).

Develco Pharma is convinced that it can successfully compete in the „Niche-market“in an environment that is characterized by increasing concentration,and which is unattainable to the giants of the pharmaceutical industry. We are convinced that our manageable organization, paired with employees and external development partners, which is characterised by diversity and willingness are ideal conditions to successfully complete projects. In this environment, niche projects have a higher priority than in large organizations. With a high level of tenacity, almost nothing will stand in the way of

Genentech’s second challenge was manifested in deciding which business model to use. Genentech had to assess if pioneer technology that creates artificial DNA could flourish in a generating money-making product. During the genesis of Genentech, a conscious decision was made to assimilate the business model of large pharmaceutical companies. The pharmaceutical industry was driven by the creation of blockbuster producing drugs. This decision to adopt this business model was made despite the industry's giants facing decline in sales from expiring patents and lack of new innovative drugs to replace them.

No two people go through life the same exact ways. Some choose to live moment to moment while others feel the need to have a grander plan for their future. People develop plans for different scenarios in their life to include what college they will attend, what profession they want to enter, the type of wedding and even, when they want to get married. Individuals who live by a plan can often be heard referencing their Plan B or five-to-ten year plan. Just as individuals like to plan, businesses also want a blueprint for their short- and long-term growth. Planning enables organizational leaders and managers to play a significant role in creating progressive objectives that enrich company productivity and

The biotech firm Amgen Inc. gives much attention and time to the planning process. Because the outcomes for a company like Amgen are often very unsure and many employees are quite sceptical about the use of such a planning, the main issue can be described as follows: